Vor Biopharma Inc. (VOR)

Vor Biopharma Statistics

Total Valuation

Vor Biopharma has a market cap or net worth of $812.79 million. The enterprise value is $324.74 million.

Market Cap	812.79M
Enterprise Value	324.74M

Important Dates

The last earnings date was Wednesday, May 13, 2026, before market open.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Vor Biopharma has 54.19 million shares outstanding. The number of shares has increased by 359.89% in one year.

Current Share Class	54.19M
Shares Outstanding	54.19M
Shares Change (YoY)	+359.89%
Shares Change (QoQ)	+111.92%
Owned by Insiders (%)	2.19%
Owned by Institutions (%)	49.37%
Float	40.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 31.15

Current Ratio	31.15
Quick Ratio	30.57
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-69.76%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-70.07%
Weighted Average Cost of Capital (WACC)	13.84%
Revenue Per Employee	n/a
Profits Per Employee	-$11.62M
Employee Count	76
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +319.16% in the last 52 weeks. The beta is 1.75, so Vor Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.75
52-Week Price Change	+319.16%
50-Day Moving Average	15.09
200-Day Moving Average	19.84
Relative Strength Index (RSI)	48.74
Average Volume (20 Days)	834,308

Short Selling Information

The latest short interest is 4.60 million, so 8.48% of the outstanding shares have been sold short.

Short Interest	4.60M
Short Previous Month	4.96M
Short % of Shares Out	8.48%
Short % of Float	11.44%
Short Ratio (days to cover)	4.94

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-343.81M
Pretax Income	-883.08M
Net Income	-883.08M
EBITDA	-341.72M
EBIT	-343.81M
Earnings Per Share (EPS)	-$46.33

Balance Sheet

The company has $491.53 million in cash and $2.94 million in debt, with a net cash position of $488.59 million or $9.02 per share.

Cash & Cash Equivalents	491.53M
Total Debt	2.94M
Net Cash	488.59M
Net Cash Per Share	$9.02
Equity (Book Value)	-150.42M
Book Value Per Share	-2.78
Working Capital	484.70M

Cash Flow

In the last 12 months, operating cash flow was -$149.89 million and capital expenditures -$758,000, giving a free cash flow of -$150.65 million.

Operating Cash Flow	-149.89M
Capital Expenditures	-758,000
Depreciation & Amortization	2.09M
Net Borrowing	n/a
Free Cash Flow	-150.65M
FCF Per Share	-$2.78

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vor Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-359.89%
Shareholder Yield	-359.89%
Earnings Yield	-108.58%
FCF Yield	-18.52%

Analyst Forecast

The average price target for Vor Biopharma is $37.88, which is 152.53% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$37.88
Price Target Difference	152.53%
Analyst Consensus	Strong Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 19, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Sep 19, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	2